Sugi Predict

Sugi Predict / Compounds / SCHEMBL9918326

SCHEMBL9918326

SCHEMBL9918326

CC(C)C1CCCN(C(=O)N(C)C)C1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ GAA P10253 2/20 0.43
▸ RAB9A P51151 2/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MAPT P10636 1/20 0.38
▸ DPP4 P27487 1/20 0.37
▸ DPP8 Q6V1X1 1/20 0.37
▸ DPP9 Q86TI2 1/20 0.37
▸ CPN1 P15169 1/20 0.37
▸ CPB2 Q96IY4 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9918307 1.00 MEN1 (0.46) MEN1KMT2ASMN1; SMN2GAARAB9A
SCHEMBL21739823 0.89 MEN1 (0.49) MEN1KMT2ASMN1; SMN2GAARAB9A
SCHEMBL25900433 0.86 HPGD (0.35) MEN1KMT2ASMN1; SMN2GAARAB9A
SCHEMBL12514730 0.81 CPN1 (0.42) MEN1KMT2AGAAALDH1A1HPGD
SCHEMBL463524 0.81 EPHX2 (0.40) GAAALDH1A1HPGDMAPTCPN1
SCHEMBL20082953 0.81 EPHX2 (0.40) GAAALDH1A1HPGDMAPTCPN1
SCHEMBL7883654 0.81 EPHX2 (0.40) GAAALDH1A1HPGDMAPTCPN1
SCHEMBL23337941 0.81 HTT (0.35) MEN1KMT2ASMN1; SMN2HPGDDPP4
SCHEMBL19735105 0.81 KMT2A (0.42) MEN1KMT2ASMN1; SMN2GAAHSD17B10
SCHEMBL13741632 0.80 ALDH1A1 (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348518-A1 HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-11-02 — — US disclosed
US-20130071415-A1 Heterocyclic Compounds as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2013-03-21 — — US disclosed
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 — — US disclosed
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 — — US disclosed
US-20120149691-A1 Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149691-A1 Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors JAK1, JAK2, JAK3 MEN1 888/4885KMT2A 774/4885SMN1; SMN2 3917/4885
US-20230348518-A1 HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS RECQL, DDX21, DDX41 MEN1 422/4885KMT2A 1132/4885SMN1; SMN2 160/4885
US-20130071415-A1 Heterocyclic Compounds as Janus Kinase Inhibitors JAK2, JAK1, JAK3 MEN1 436/4885KMT2A 533/4885SMN1; SMN2 4086/4885
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors JAK2, JAK1, JAK3 MEN1 440/4885KMT2A 628/4885SMN1; SMN2 4199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.